147 related articles for article (PubMed ID: 30758911)
41. [Unexpected positive outcome following rituximab treatment in a patient with pemphigus vegetans resistant to conventional therapies: a case report].
Barbach Y; Baybay H; Mrabat S; Chaouche M; Elloudi S; Mernissi FZ
Pan Afr Med J; 2019; 32():101. PubMed ID: 31223391
[TBL] [Abstract][Full Text] [Related]
42. First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: Preliminary retrospective study with a seven year follow-up.
Ahmed AR; Nguyen T; Kaveri S; Spigelman ZS
Int Immunopharmacol; 2016 May; 34():25-31. PubMed ID: 26919279
[TBL] [Abstract][Full Text] [Related]
43. Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris.
Sami N; Qureshi A; Ruocco E; Ahmed AR
Arch Dermatol; 2002 Sep; 138(9):1158-62. PubMed ID: 12224976
[TBL] [Abstract][Full Text] [Related]
44. A rare presentation of oral pemphigus vulgaris as multiple pustules.
Rimal J; Sumanth KN; Ongole R; George T; Chatterjee S
Kathmandu Univ Med J (KUMJ); 2007; 5(4):541-5. PubMed ID: 18604092
[TBL] [Abstract][Full Text] [Related]
45. Aspergillus endocarditis: Diagnostic criteria and predictors of outcome, A retrospective cohort study.
Meshaal MS; Labib D; Said K; Hosny M; Hassan M; Abd Al Aziz S; Elkholy A; Anani M; Rizk H
PLoS One; 2018; 13(8):e0201459. PubMed ID: 30092074
[TBL] [Abstract][Full Text] [Related]
46. Relevance of rituximab therapy in pemphigus vulgaris: analysis of current data and the immunologic basis for its observed responses.
Feldman RJ; Ahmed AR
Expert Rev Clin Immunol; 2011 Jul; 7(4):529-41. PubMed ID: 21790294
[TBL] [Abstract][Full Text] [Related]
47. Rituximab in refractory pemphigus vulgaris.
Sorce M; Aricò M; Bongiorno MR
Dermatol Ther; 2008 Jul; 21 Suppl 1():S6-9. PubMed ID: 18727815
[TBL] [Abstract][Full Text] [Related]
48. Oral Ulcers as an Initial Presentation of Juvenile Pemphigus: A Case Report.
Chen IH; Mu SC; Tsai D; Chou YY; Wang LF; Wang LJ
Pediatr Neonatol; 2016 Aug; 57(4):338-42. PubMed ID: 24295781
[TBL] [Abstract][Full Text] [Related]
49. Pemphigus vulgaris: update on etiopathogenesis, oral manifestations, and management.
Scully C; Challacombe SJ
Crit Rev Oral Biol Med; 2002; 13(5):397-408. PubMed ID: 12393759
[TBL] [Abstract][Full Text] [Related]
50. Treatment of pemphigus vulgaris: part 1 - current therapies.
Yanovsky RL; McLeod M; Ahmed AR
Expert Rev Clin Immunol; 2019 Oct; 15(10):1047-1060. PubMed ID: 31566020
[No Abstract] [Full Text] [Related]
51. Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris.
Olszewska M; Kolacinska-Strasz Z; Sulej J; Labecka H; Cwikla J; Natorska U; Blaszczyk M
Am J Clin Dermatol; 2007; 8(2):85-92. PubMed ID: 17428113
[TBL] [Abstract][Full Text] [Related]
52. Localized Kaposi's sarcoma in a patient with pemphigus vulgaris.
Avalos-Peralta P; Herrera A; Ríos-Martín JJ; Pérez-Bernal AM; Moreno-Ramírez D; Camacho F
J Eur Acad Dermatol Venereol; 2006 Jan; 20(1):79-83. PubMed ID: 16405614
[TBL] [Abstract][Full Text] [Related]
53. Evaluation of cyclophosphamide pulse therapy as an adjuvant to oral corticosteroid in the management of pemphigus vulgaris.
Sharma VK; Khandpur S
Clin Exp Dermatol; 2013 Aug; 38(6):659-64. PubMed ID: 23837939
[TBL] [Abstract][Full Text] [Related]
54. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris.
Chams-Davatchi C; Esmaili N; Daneshpazhooh M; Valikhani M; Balighi K; Hallaji Z; Barzegari M; Akhyani M; Ghodsi SZ; Seirafi H; Nazemi MJ; Mortazavi H; Mirshams-Shahshahani M
J Am Acad Dermatol; 2007 Oct; 57(4):622-8. PubMed ID: 17583373
[TBL] [Abstract][Full Text] [Related]
55. Etiology of pyrexia in pemphigus patients: a dermatologist's enigma.
Qadim HH; Hasani A; Zinus BM; Orang NJ; Hasani A
Indian J Dermatol Venereol Leprol; 2012; 78(6):774. PubMed ID: 23075657
[No Abstract] [Full Text] [Related]
56. Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases.
Grundmann-Kollmann M; Korting HC; Behrens S; Kaskel P; Leiter U; Krähn G; Kerscher M; Peter RU
J Am Acad Dermatol; 1999 Jun; 40(6 Pt 1):957-60. PubMed ID: 10365927
[TBL] [Abstract][Full Text] [Related]
57. Comparison between the efficacy of intralesional rituximab versus intralesional triamcinolone in the treatment refractory Pemphigus Vulgaris lesions: A randomized clinical trial.
Iraji F; Danesh F; Faghihi G; Siadat A; Mokhtari F; Talakoob M; Hafezi H
Int Immunopharmacol; 2019 Aug; 73():94-97. PubMed ID: 31082727
[TBL] [Abstract][Full Text] [Related]
58. Pulsed intravenous cyclophosphamide and methylprednisolone therapy in refractory pemphigus.
Saha M; Powell AM; Bhogal B; Black MM; Groves RW
Br J Dermatol; 2010 Apr; 162(4):790-7. PubMed ID: 19922532
[TBL] [Abstract][Full Text] [Related]
59. Assessment of the adjuvant effect of tacrolimus in the management of pemphigus vulgaris: A randomized controlled trial.
Dastgheib L; Sadati MS; Baghernejhad M
J Dermatolog Treat; 2015 Feb; 26(1):90-3. PubMed ID: 24552352
[TBL] [Abstract][Full Text] [Related]
60. Future therapies for pemphigus vulgaris: Rituximab and beyond.
Huang A; Madan RK; Levitt J
J Am Acad Dermatol; 2016 Apr; 74(4):746-53. PubMed ID: 26792592
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
